|
|
|
The PROSPER Trial: Enzalutamide Demonstrates Significant Improvement in Overall Survival in Nonmetastatic Castration-Resistant Prostate Cancer
|
|
Cora Sternberg, MD, FACP
|
| Cora Sternberg shares the final analysis of the PROSPER trial assessing enzalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC).
|
|
|
|
|
|
|
|
|
|
|
|
|
Best of ASCO 2020 Prostate Cancer
|
|
A. Oliver Sartor, MD
|
| Oliver Sartor joins Alicia Morgans to speak about several prostate cancer studies making an impact on the diagnosis of prostate cancer and the treatment paradigm for this disease.
|
|
|
|
|
|
|
|
|
|
|
|
|
HERO Phase III Trial: Results Comparing Relugolix, an Oral GnRH Receptor Antagonist Vs. Leuprolide Acetate for Advanced Prostate Cancer
|
|
Neal Shore, MD, FACS
|
| Neal Shore joins Alicia Morgans to discuss the results of the HERO phase 3 trial comparing the safety and efficacy of relugolix with leuprolide acetate in advanced prostate cancer patients.
|
|
|
|
|
|
|
|
|
|
 |
|
| CONDOR: Study of 18F-DCFPyL PET/CT Imaging in Patients with Suspected Recurrence of Prostate Cancer |
| Michael J. Morris, MD |
| Michael Morris, Oliver Sartor and Alicia Morgans discuss the CONDOR study, the second of two prospective clinical trials designed in collaboration with the FDA to demonstrate the diagnostic performance of PyL in patients with biochemically recurrent prostate cancer. |
|
|
|
|
|
|
|
|
|
|
|
|
|
EDITOR SELECTED ABSTRACTS AND COMMENTARIES
|
|
|
|
|
| Cancer Care in the Time of COVID: Assessing Impact and Future Directions
|
| Jeremy L. Warner, MD, MS
|
| In this ASCO 2020 presentation, Jeremy Warner explains the origins of the COVID-19 and Cancer Consortium. As of today, there are 106 participating centers across the USA and Canada. The Mission of the CCC-19 is to collect and disseminate prospective, granular, uniformly organized information on people with cancer who are diagnosed with COVID-19 - at scale and as rapidly as possible.
|
|
|
|
|
|
| Looking Back on COVID-19 in Order to Move Forward
|
| Giuseppe Curigliano, MD, Ph.D.
|
| At the virtual ASCO 2020 annual meeting, Giuseppe Curigliano summarized and reviewed two presentations: the TERAVOLT and COVID-19 Cancer Consortium (CCC-19) initiatives.
|
|
|
|
|
|
| CONDOR The Impact of PSMA-targeted Imaging with 18F-DCFPyL-PET/CT on Clinical Management of Patients with Biochemically Recurrent Prostate Cancer
|
| Michael J. Morris, MD
|
| Several PSMA tracers are under development, including 18F-DCFPyL, a fluorinated PSMA-targeted agent which has shown has shown reliable diagnostic performance in detecting metastatic or recurrent prostate cancer. This study evaluates how PyL PET/CT may change clinical management for these men with biochemical recurrence.
|
|
|
|
|
|
| First-in-Human Phase I Study of HPN424, a Tri-Specific Half-Life Extended PSMA-Targeting T-Cell Engager in Patients with mCRPC |
| Johanna C. Bendell, MD |
| At the 2020 ASCO virtual annual meeting Johanna Bendell and colleagues presented results of a phase one study initiated to evaluate HPN424 in patients with metastatic castration resistant prostate cancer. |
|
|
|
|
|
|
|
|
|
| Phase 3 PROSPER Trial Results: Enzalutamide Demonstrates Significant Improvement in OS in Patients with nmCRPC
|
| Cora N. Sternberg, MD, FACP
|
| Enzalutamide is an FDA approved androgen receptor antagonist used in the treatment of essentially every phase of advanced prostate cancer, from metastatic hormone-sensitive prostate cancer to metastatic and non-metastatic castration-resistant prostate cancer. The approval of enzalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC) was based on the PROSPER trial.
|
|
|
|
|
|
| Results from the HERO Phase III Trial Comparing Relugolix, an Oral GnRH Receptor Antagonist, versus Leuprolide Acetate for Advanced Prostate Cancer
|
| Neal Shore, MD, FACS
|
| There is evidence that ADT increases the risk of adverse cardiovascular events such as myocardial infarction, stroke, and cardiovascular mortality, possibly by exacerbating cardiovascular risk factors. In this presentation, Dr. Shore provides data that shows that cardiovascular disease is now the leading cause of mortality in men with prostate cancer.
|
|
|
|
|
|
| Short-Term Adjuvant Versus Neoadjuvant Hormone Therapy in Localized Prostate Cancer: A Pooled Individual Patient Analysis of Two Phase III Trials
|
| Daniel E Spratt, MD
|
| Intermediate and high-risk localized prostate cancers can be treated with surgery or the combination of radiotherapy and hormonal therapy. The optimal timing of hormonal therapy in relation to radiotherapy for localized prostate cancer is an area of active study.
|
|
|
|
|
|
| Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
|
| Abstract
|
| In this double-blind, phase 3 trial, men with nonmetastatic, castration-resistant prostate cancer (defined on the basis of conventional imaging and a PSA doubling time of ≤10 months) who were continuing to receive androgen-deprivation therapy were randomly assigned (in a 2:1 ratio) to receive enzalutamide at a dose of 160 mg or placebo once daily.
|
|
|
|
|
|
| Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
|
| Abstract
|
| In this phase 3 trial, the authors randomly assigned patients with advanced prostate cancer, in a 2:1 ratio, to receive relugolix (120 mg orally once daily) or leuprolide (injections every 3 months) for 48 weeks. The primary end point was sustained testosterone suppression to castrate levels (<50 ng per deciliter) through 48 weeks.
|
|
|
|
|
|
|
